Expanded Use PK of Dapivirine Vaginal Ring

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified September 2013 by International Partnership for Microbicides, Inc.
Sponsor:
Information provided by (Responsible Party):
International Partnership for Microbicides, Inc.
ClinicalTrials.gov Identifier:
NCT01952561
First received: September 17, 2013
Last updated: September 24, 2013
Last verified: September 2013

September 17, 2013
September 24, 2013
November 2013
March 2014   (final data collection date for primary outcome measure)
dapivirine pharmacokinetics in plasma [ Time Frame: 1,2,4,8 or 12 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01952561 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Expanded Use PK of Dapivirine Vaginal Ring
An Open-label, Parallel-group Pharmacokinetic Trial in Healthy HIV-negative Women to Characterize the Release Profile of Dapivirine Delivered by a Silicone Matrix Ring (Ring 004), Containing 25 mg of Dapivirine, Over Various Ring Use Periods

Study will evaluate the vaginal and blood pharmacokinetics of dapivirine from a vaginal ring containing 25 mg worn for 1, 2, 4, 8 or 12 months.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Pharmacokinetics
Drug: dapivirine ring
  • Experimental: 2 weeks
    Intervention: Drug: dapivirine ring
  • Experimental: 1 week
    Intervention: Drug: dapivirine ring
  • Experimental: 4 weeks
    Intervention: Drug: dapivirine ring
  • Experimental: 8 weeks
    Intervention: Drug: dapivirine ring
  • Experimental: 12 weeks
    Intervention: Drug: dapivirine ring
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
40
May 2014
March 2014   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  1. Women 18 and ≤ 40 years of age who can give written informed consent
  2. Available for all visits and consent to follow all procedures scheduled for the trial
  3. Healthy, based on medical history, vital signs, physical examination, urinalysis, laboratory evaluations for genital infections, and laboratory evaluations for haematology and chemistry
  4. HIV-negative as determined by an HIV test at the time of enrolment
  5. On a stable form of contraception, defined as:

    • A stable oral contraceptive regimen for at least 2 months prior to enrolment, OR
    • Transdermal contraceptive patch for at least 3 months prior to enrolment, OR
    • Long-acting progestins for at least 6 months prior to enrolment, OR
    • An IUD inserted at least 3 months prior to enrolment, OR
    • Have undergone surgical sterilisation at least 3 months prior to enrolment AND willing to use oral contraceptives if necessary to delay menstruation during the vaginal sampling period
  6. Upon pelvic examination at the time of enrolment, the cervix and vagina appear normal as determined by the Investigator/Physician
  7. Asymptomatic for genital infections at the time of enrolment
  8. Willing to refrain from the use of topical vaginal medications, vaginal products or objects
  9. Documentation of no abnormality on cervical cytology, including grossly bloody smear, within 90 days prior to screening
  10. Willing to refrain from participation in any other research trial for the duration of this trial
  11. Willing to provide adequate locator information for trial retention purposes and be reachable per local standard procedures, e.g. by home visit or telephone, or via family or close neighbour contacts
  12. Willing to agree to abstain from all the following for a total of 2 days (48 hours) prior to each trial visit:

    • Penile-vaginal intercourse
    • Oral contact with her genitalia
  13. Hepatitis B and C negative at the time of enrolment.

Key Exclusion Criteria:

  1. Currently pregnant or had their last pregnancy outcome within 3 months prior to screening
  2. Currently breast-feeding
  3. Currently or within two months of participation in any other clinical research trial involving investigational or marketed products prior to screening
  4. Untreated symptomatic urogenital infections, e.g. urinary tract or other sexually transmitted infections, or other gynaecological conditions such as vaginal itching, pain, or discharge, within 2 weeks prior to enrolment
  5. Have a Grade 2 or higher pelvic examination finding, according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events;
  6. History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction, incontinence or urge incontinence
  7. Current vulvar or vaginal symptoms/abnormalities that could influence the trial results
  8. Cervical cytology at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation
  9. Symptomatic genital herpes simplex virus (HSV) infection or a history of genital herpetic infection
  10. Any Grade 2, 3 or 4 haematology, biochemistry or urinalysis laboratory abnormality at baseline (screening) according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events;
  11. Unexplained, abnormal bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrolment
  12. Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex or silicone
  13. Any serious acute, chronic or progressive or signs of cardiac disease, renal failure, or severe malnutrition
  14. Have undergone a hysterectomy
  15. Any condition(s) that, in the opinion of the Investigator, might interfere with adherence to trial requirements or evaluation of the trial objectives.
Female
18 Years to 40 Years
Yes
Not Provided
 
NCT01952561
IPM 034
No
International Partnership for Microbicides, Inc.
International Partnership for Microbicides, Inc.
Not Provided
Not Provided
International Partnership for Microbicides, Inc.
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP